Skip to content
  • Brazil
  • Canada
  • Europe
  • India
  • Italy
  • Japan
  • Korea
  • Latam
  • Spain
  • Taiwan
  • The Middle East
  • Turkey
  • United Kingdom
  • United States
  • Country/Region
  • No block ID is set

  • Clinic Portal
    • +0034963905310
  • Request Information
  • +34 96 390 53 10
  • Part of brands: |
InternationalInternational
  • Country/Region
  • Part of brands: |
  • Patient Journey
    • Before Pregnancy
    • IVF Process
    • Healthy pregnancy
    • After birth
  • Reproductive Health
    • Specialists
      • ERA
      • ERA insight Hub
      • ALICE
      • EMMA
      • EndomeTRIO
      • Infertility Panels
      • EMBRACE
      • PGT-A
      • PGT-A Plus
      • PGT-M
      • PGT-SR
      • CGT
      • NACE
      • Zenit
      • POC Portfolio
      • SAT
      • Newborn Screening
  • Diagnostics
  • About us
    • Igenomix Research
    • About Igenomix
    • Igenomix Worldwide
  • Academy
  • Blog
Genetic Testing Solutions > CGT

CGT: Carrier Genetic Test

Determines the risk of having a child with a genetic disease

CGT Carrier Genetic Test
    • Technical Overview
    • CGT Gene List
    • Residual risk
    • Documentation
    • Scientific evidence
    • I’m not a health specialist
  • CGT Carrier Genetic Test

    Inherited disorders represent 20% of the causes of infant mortality in developed countries

    CGT Carrier Genetic Test

    Sensitivity of 98%

    igenomix

    Different CGT options available: CGT Essential, CGT Plus and CGT Exome

    Test results in 20 working days

    Interested in learning more?

    Request information
    Or Email us at supportspain@igenomix.com
    Overview
    • CGT
    • Benefits
    • Indications

    What is CGT test?

    • CGT is an advanced carrier genetic test, which determines whether a couple are carriers of genetic mutations that could be transmitted to their children.
    • CGT uses Next-Generation Sequencing (NGS) to analyse a wide panel of disorders including as Cystic Fibrosis, Spinal Muscular Atrophy, Fragile-X Syndrome.
    Our New Universal approach to expanded carrier screening using Whole Exome Sequencing
    CGT Carrier Genetic Test

    CGT Exome

    Premium Expanded Panel compatible with most carrier platforms in the market.

    CGT Carrier Genetic Test

    CGT Plus

    Based on the recommendation of medical societies.

    CGT Bank

    Exclusive panel for Gamete donors

    More information about genes and mutations
    CGT Carrier Genetic Test

    Why use our CS Exome based?

    • Is a clinically validated genetic screening test based on Next-Generation Sequencing (NGS).
    • Allows for testing of all known recessive conditions, increasing the overall detection rate and minimizing the global residual risk.
    • Maximizes IVF applications, matching possible with all genetic lab tests in the market.
    • Our different CGT options, tailored to each patient’s needs, make it the most complete test available.
    • Any upgrade possible at a later date if required.
    • Genetic Counselling
    • Exome sequencing offers added value for a future analysis of a given patient providing analytical possibilities in an adverse event of a newborn with a genetic condition.

    Who should use CGT test?

    • Couples who plan on forming a family and want to know the risk of transmitting hereditary disorders to their children
    • Patients planning an assisted reproduction treatment
    • Patients planning a treatment with donor sperm or eggs

    Most carriers of genetic mutations don’t have a family history of these disorders.

    CGT Carrier Genetic Test

    Test limitations

    • The sensitivity of the test is 98%.
    • We only analyze genes on the list available at www.cgt.igenomix.com, reporting results based on knowledge current at the time of testing. Therefore, only genes included in this list will be detected.
    • The method is based on analysis by massive parallel sequencing and bioinformatics, studying all the exons of the genes included on our gene list. This includes adjacent intronic regions before or after position +5 and -5. Variants located outside the gene regions studied, such as gene-expression regulatory regions or intronic regions before or after position +5 and -5 are not detected.
    • No inversions, deletions, or duplications over 20 nucleotides long that are not referred to in the list available at www.cgt.igenomix.com are studied.
    • Germ mosaics (mutations only present in gametes) are not detected by this analysis because the DNA material studied is obtained from a blood sample.
    • A negative result for the genes indicated does not exclude the possibility that a de novo mutation may appear in the offspring.
    Documentation
    • CGT Specialists' documents

    Clinical Sheets

    Download

    Brochure

    Download

    Instructions

    Download
    Scientific evidence

    Relevant related studies:

    The development of the CGT panel and the concept of comprehensive carrier screening was published in a paper by Martin et al, 2015 (Fertil Steril. 2015 Nov; 104(5):1286-93).

    An analysis of preconception carrier screening and genetic matching with donor gametes was presented in an abstract by Egea et al, 2016 (Fertil Steril. 2016 Oct; e329).

    Results discussing the use of carrier screening to predict the risk of disorders in the Middle-Eastern population was published as an abstract by Martin et al, 2018 (Reproductive Biomedicine Online 2018; e10)

    FAQs

    Opening hours, contact details, lab address...

    User manual

    If you're a little lost with this technical information...

    Can we help you?

    I’m not a health specialist

    Igenomix and fertility

    We work to make a world in which infertility is no longer an impossible barrier. Together with clinics and fertility specialists worldwide, we investigate human reproduction to change the lives of those who are trying to conceive.

    Learn more about Igenomix

    Other services

    PGT-M Preimplantation Genetic Testing

    PGT-M

    Prevents the transmission of single gene disorders

    More information
    NACE Non-invasive prenatal test

    NACE

    Minimizes unnecessary amniocentesis

    More information

    Igenomix is in the media

    WE GUIDE YOU

    Fertility
    Inherited diseases prevention
    Healthy pregnancy

    To see the accreditation certificate, associated technical annex and list of accredited tests, click on this link.

    OUR SERVICES

    Genetic testing solutions
    For patients
    How to send a sample?
    User manual

    ABOUT US

    About Igenomix
    Contact
    Quality
    Complaints
    Work with us
    Terms and conditions

    FOLLOW IGENOMIX

      + 96 390 53 10
      Write us
    • Brazil
    • Canada
    • Europe
    • India
    • Italy
    • Japan
    • Korea
    • Latam
    • Spain
    • Taiwan
    • The Middle East
    • Turkey
    • United Kingdom
    • United States
    Country/Region

    [2024] © Igenomix Privacy Page Quality policy Legal note Cookies policy

    Request Information


    • Patient Journey
      • Before Pregnancy
      • IVF Process
      • Healthy pregnancy
      • After birth
    • Reproductive Health
      • Specialists
        • ERA
        • ERA insight Hub
        • ALICE
        • EMMA
        • EndomeTRIO
        • Infertility Panels
        • EMBRACE
        • PGT-A
        • PGT-A Plus
        • PGT-M
        • PGT-SR
        • CGT
        • NACE
        • Zenit
        • POC Portfolio
        • SAT
        • Newborn Screening
    • Diagnostics
    • About us
      • Igenomix Research
      • About Igenomix
      • Igenomix Worldwide
    • Academy
    • Blog
    • Country/Region
    • +34 96 390 53 10
    • Clinic Portal
    • Request Information